Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study
- Yunus Çolak1,2,3,
- Børge G. Nordestgaard1,2,3,
- Jørgen Vestbo4,
- Peter Lange2,3,5,6 and
- Shoaib Afzal1,2,3⇑
- 1Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- 2The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- 3Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- 4Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Manchester Academic Health Science Centre, University of Manchester, and Manchester University NHS Foundation Trust, Manchester, United Kingdom
- 5Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark
- 6Department of Internal Medicine, Section of Respiratory Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- Shoaib Afzal, MD, PhD, DMSc, Associate Professor, Consultant, Department of Clinical Biochemistry and the Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Borgmester Ib Juuls Vej 73, Entrance 7, 4. Floor, M3, Herlev, DK-2730. E-mail: shoaib.afzal{at}regionh.dk
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Çolak reports personal fees from Boehringer Ingelheim, AstraZeneca, and Sanofi Genzyme outside the submitted work.
Conflict of interest: Dr. Nordestgaard has nothing to disclose.
Conflict of interest: Dr. Vestbo reports personal fees from GlaxoSmithKline, Chiesi pharmaceuticals, Boehringer-Ingelheim, Novartis, Almirall, AstraZeneca, personal fees from Bioxydyn, personal fees from GlaxoSmithKline, Chiesi pharmaceuticals, Novartis, AstraZeneca, Boehringer-Ingelheim, personal fees from GlaxoSmithKline, AstraZeneca, Ferring, outside the submitted work.
Conflict of interest: Dr. Lange reports grants and personal fees from Almirall, grants and personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, personal fees from Novartis, grants and personal fees from GSK, personal fees from Nycomed, personal fees from Pfizer, personal fees from Mundipharma, outside the submitted work.
Conflict of interest: Dr. Afzal has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received September 3, 2020.
- Accepted November 13, 2020.
- Copyright ©ERS 2020